We narrowed to 90 results for: ATR

#199773-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP13863 - pAAV-AiE0888m_C4-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3863) (#199773). In addition to the viral particles, you will also receive purified AiP13863 - pAAV-AiE0888m_C4-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3863) plasmid DNA. SYFP2 expression in midbrain dopamine neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

July 15, 2024

Academic Institutions and Nonprofits only

#214846-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP13755: pAAV-AiE0743m_3xC2-minBG-ChR2(H134R)-EYFP-WPRE3-BGHpA (Alias: CN3755) (#214846). In addition to the viral particles, you will also receive purified AiP13755: pAAV-AiE0743m_3xC2-minBG-ChR2(H134R)-EYFP-WPRE3-BGHpA (Alias: CN3755) plasmid DNA. minBG-driven expression of ChR2(H134R)-EYFP in striatal cholinergic neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

Nov. 13, 2024

Academic Institutions and Nonprofits only

#199775-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP13778 - pAAV-AiE0450h-minBG-iCre(R297T)-BGHpA (Alias: CN3778) (#199775). In addition to the viral particles, you will also receive purified AiP13778 - pAAV-AiE0450h-minBG-iCre(R297T)-BGHpA (Alias: CN3778) plasmid DNA. Cre recombinase expression in striatal medium spiny neurons. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

July 15, 2024

Academic Institutions and Nonprofits only

#24593-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-pgk-Cre (#24593). In addition to the viral particles, you will also receive purified AAV-pgk-Cre plasmid DNA. Cre expression under the PGK promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons.

Patrick Aebischer

July 24, 2017

Academic Institutions and Nonprofits only

#128317-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-JRGECO1a (#128317). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-JRGECO1a plasmid DNA. EF1a-driven, Flp-dependent expression of the biosensor jRGECO1a. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

March 18, 2024

Academic Institutions and Nonprofits only

#105921-AAV2

Ready-to-use AAV2 particles produced from pAAV-CBh-mKate2-IRES-MCS (WT-WT) (#105921). In addition to the viral particles, you will also receive purified pAAV-CBh-mKate2-IRES-MCS (WT-WT) plasmid DNA. Control mKate2 expression AAV with two wild-type ITR sequences. These AAV preparations are suitable purity for injection into animals.

Marcella Patrick

Nov. 13, 2018

Academic Institutions and Nonprofits only

#128434-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-tdTomato (#128434). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-tdTomato plasmid DNA. EF1a-driven, Flp-dependent expression of tdTomato. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

March 12, 2021

Academic Institutions and Nonprofits only

#128315-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-GCaMP6f (#128315). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-GCaMP6f plasmid DNA. EF1a-driven, Flp-dependent expression of calcium sensor GCaMP6f. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

March 12, 2021

Academic Institutions and Nonprofits only

#171027-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO-ChrimsonR-tdTomato (#171027). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-ChrimsonR-tdTomato plasmid DNA. Flp-dependent, Ef1a-driven expression of ChrimsonR-tdTomato fusion for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

June 26, 2024

Academic Institutions and Nonprofits only

#171027-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-fDIO-ChrimsonR-tdTomato (#171027). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO-ChrimsonR-tdTomato plasmid DNA. Flp-dependent, Ef1a-driven expression of ChrimsonR-tdTomato fusion for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Patricia Jensen

Sciolino et al Sci Adv. 2022 Aug 19;8(33):eabn9134. doi

July 21, 2023

Academic Institutions and Nonprofits only